LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT OF THE COMPANY

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information on the latest product development of the Company.

Reference is made to the annual report of the Company for the year ended 31 December 2015 (the "**Annual Report**"). As disclosed in the Annual Report, the Company had completed the clinical trial reports in Europe and twelve-month follow-up visit in the People's Republic of China ("**PRC**") for the LAmbre™ left atrial appendage ("**LAA**") occluder system and submitted the registration application for the Conformité Européenne ("**CE**") certification approval in Europe.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 15 June 2016, the LAmbre™ LAA occluder system has been granted with the CE certificate in Europe, which becomes the only LAA closure product of a Chinese brand obtained with such certification.

The Company has started its research on the LAA occluder system since 2003 and officially commenced the research and development of the LAA closure product in 2010. The LAmbre™ LAA occluder was designed for left atrial appendage closure via percutaneous transcatheter procedure, which is considered as an alternative to anticoagulation in patients with atrial fibrillation at risk of stroke. The main design of the LAmbre™ LAA occluder consists of a distal umbrella and a proximal cover disc connected by a short sleeve. In addition, the occluder design would allow

the device to adapt to various LAA anatomies and sizes, fully re-capture and re-position during the whole procedure, and deliver with small sheath. These characteristics make LAmbre™ LAA occluder system safe, easy to use with a short learning curve for physicians. Through clinical trials, the LAmbre™ LAA occluder system has received much praise and was highly regarded from doctors and patients globally. It is expected that the LAmbre™ LAA occluder system will occupy the mainstream market of Europe and other areas and will open the large market space.

The Board believes that the approval of the CE certificate for the LAmbre™ LAA occluder system not only marked the entrance of the Company's innovative and cutting-edge LAA closure product into the European market, but also represented a milestone towards the success on the Company's overall strategy in globalising such system. The Company will benefit from its rapid expansion into the global market and become one of the leading companies in the field, thereby promoting the steady development of the Group.

Going forward, the Company will continue its commitment in independent innovation and development, in order to benefit patients globally through its minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and
Chief Executive Officer

Hong Kong, 16 June 2016

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. XIAO Ying being executive Directors; Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.